Perrigo Company plc - Form 8-K Summary
Business Context and Reporting Period
Perrigo Company plc, a global pharmaceutical company incorporated in Ireland, filed this Current Report on Form 8-K on August 9, 2022. The filing announces the release of earnings results for the second quarter ended July 2, 2022. The company's ordinary shares and various notes are registered on the New York Stock Exchange.
Key Financial Metrics
This Form 8-K serves as a notification of the earnings release and does not contain specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. The actual financial figures are contained in the attached press release (Exhibit 99.1), which is not included in the provided text.
The filing details the methodology for Non-GAAP financial measures, which exclude items such as:
- Acquisition and integration-related charges and contingent consideration adjustments
- Amortization expense related to acquired intangible assets
- Restructuring charges and termination benefits
- Loss on early debt extinguishment
- Unusual litigation
- Impairment charges
- Foreign currency translation movements
Material Changes and Adjustments
The filing outlines specific adjustments made to derive Non-GAAP results for the three and six months ended July 2, 2022, compared to the prior year periods. Notable items excluded in the current period (Three Months Ended July 2, 2022) include a loss on early debt extinguishment, which was not listed as an adjustment for the same period in 2021. Conversely, the prior year period (Three Months Ended July 3, 2021) included adjustments for indirect RX business support costs and separation and reorganization expenses that are not listed for the current period.
Guidance, Outlook, and Management Commentary
Management utilizes these Non-GAAP measures for planning, forecasting, and evaluating segment performance. The company states that these measures facilitate comparability between periods and with competitors by removing the impact of exogenous factors like foreign exchange and one-time charges. No specific forward-looking guidance or numerical outlook is provided within this filing text.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release) for specific GAAP and Non-GAAP revenue, net income, and EPS figures.
- Verify the magnitude of the "loss on early debt extinguishment" impacting the current quarter.
- Assess the impact of foreign currency translation on reported results versus constant currency growth.
- Confirm the status of restructuring charges and their effect on future cash flows.
- Examine the reconciliation between GAAP and Non-GAAP tax adjustments.